🔎 Trials Near Me

Dachaigh › Aillse sa bhlaire › Oklahoma › Oklahoma City

Sgrùdaidhean clionaigeach Aillse sa bhlaire ann an Oklahoma City, OK

Tha aon sgrùdadh airson Aillse sa bhlaire a’ lorg phàirtichean aig làrach ann no faisg air Oklahoma City. Fosglaidh e gus faicinn cò as urrainn pàirt a ghabhail agus mar a chuireas tu fios air an sgioba.

Teacsa sgrùdaidh oifigeil (Beurla)

A’ fastadh airson sgrùdadh an seo? Seall e aig mullach na duilleige seo — $99 airson 30 latha →

Testing the Addition of an Anti-Cancer Drug, Gemcitabine, to Usual Treatment (BCG Alone) in People Whose Non-Muscle Invasive Bladder Cancer (NMIBC) Came Back After Prior BCG Therapy

A’ fastadhÌre 3
  • University of Oklahoma Health Sciences Center, Oklahoma City
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 2 Dàmh 2026 · NCT07000084

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

A’ fastadhSgrùdadh amharcFàilte do shaor-thoilich fhallain
  • Mercy Hospital Oklahoma City, Oklahoma City
Aoisean 40 gu 75 · Gach gnè · Air ùrachadh 2 Dàmh 2026 · NCT05334069

Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to Radiation Therapy Compared to the Usual Chemotherapy Treatment During Radiation Therapy for Bladder Cancer, PARRC Trial

A’ fastadhÌre 2
  • University of Oklahoma Health Sciences Center, Oklahoma City
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 2 Dàmh 2026 · NCT06770582

Combining Immunotherapy and Radiation Therapy to Help Patients Avoid Bladder Removal After Treatment Shrinks Muscle Invasive Bladder Cancer, BRIGHT Trial

A’ fastadhÌre 2
  • University of Oklahoma Health Sciences Center, Oklahoma City
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 1 Dàmh 2026 · NCT07061964

Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors

A’ fastadhÌre 2
  • University of Oklahoma Health Sciences Center, Oklahoma City
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 30 Sult 2026 · NCT03866382

The Vanguard Study: Testing a New Way to Screen for Cancer

A’ fastadhFàilte do shaor-thoilich fhallain
  • University of Oklahoma Health Sciences Center, Oklahoma City
Aoisean 45 gu 75 · Gach gnè · Air ùrachadh 2 Sult 2026 · NCT06995898

FORAGER-1: A Study of Vepugratinib (LY3866288; LOXO-435) in Participants With Cancer With a Change in a Gene Called FGFR3

A’ fastadhÌre 1
  • University of Oklahoma - Health Sciences Center, Oklahoma City
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 20 Lùna 2026 · NCT05614739

Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients Receiving the Usual Chemotherapy Treatment for Bladder Cancer, ARCHER Study

A’ fastadhÌre 3
  • University of Oklahoma Health Sciences Center, Oklahoma City
  • Mercy Hospital Oklahoma City, Oklahoma City
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 18 Lùna 2026 · NCT07097142

A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2

A’ fastadhÌre 2
  • OU Health Stephenson Cancer Center, Oklahoma City
  • OU Medical Center, Oklahoma City
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 22 Iuch 2026 · NCT04879329

A Study of Sigvotatug Vedotin in Advanced Solid Tumors

A’ fastadhÌre 1
  • OU Health University of Oklahoma Medical Center, Oklahoma City
  • Stephenson Cancer Center (chemo location), Oklahoma City
  • University of Oklahoma Health Science Center, Oklahoma City
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 6 Iuch 2026 · NCT04389632

Predicting Response to Immunotherapy From Analysis of Live Tumor Biopsies (ELEPHAS-05)

A’ fastadhSgrùdadh amharc
  • Mercy Hospital - OKC, Oklahoma City
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 29 Ògmh 2026 · NCT07327489

Sgrùdaidhean Aillse sa bhlaire ann am bailtean eile

Sgrùdaidhean eile ann an Oklahoma City

Bho ClinicalTrials.gov, dàta air a thogail 5 Dàmh 2026. Bidh gach sgrùdadh a’ suidheachadh a chuidi fhèin; bidh an sgioba sgrùdaidh a’ co-dhùnadh cò as urrainn pàirt a ghabhail.